The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in ...

Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel embolic system.

Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced ...

The global transcatheter embolization and occlusion (TEO) devices market is set for rapid growth, driven by increasing preference for minimally invasive procedures in oncology, neurology, and other ...

(9926.HK) (“Akeso” or the “Company”) announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China’s National ...